A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants

A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 in Healthy Participants

The purposes of this study are to:

1. evaluate potential interactions between taladegib (ENV-101) and current standard-of-care (SOC) therapies for idiopathic pulmonary fibrosis (IPF), including nintedanib and pirfenidone, and
2. more fully characterize the pharmacokinetics (PK) of taladegib (i.e., how the body absorbs, distributes, metabolizes and excretes taladegib).

This study will enroll 4 cohorts (groups) of participants. Each cohort will experience a different duration of treatment and sequestering (being housed) at the clinical site, followed by a 14-day follow-up period for safety evaluation. The longest duration of treatment for any cohort is 30 days.

Study Overview

• Status: Recruiting
• Conditions: Idiopathic Pulmonary Fibrosis
• Intervention / Treatment: Drug: taladegib; Drug: nintedanib; Drug: pirfenidone; Drug: pirfenidone

• Study Type: Interventional
• Enrollment (Estimated): 57
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Endeavor Clinical Trials; Phone Number: 1-858-727-3199; Email: ebmclinical@endeavorbiomedicines.com

Study Locations

• Australia
  • Queensland
    • Brisbane, Queensland, Australia, 4006
      • Recruiting
      • Research Site
      • Contact: Endeavor Clinical Trials; Phone Number: 1-858-727-3199; Email: ebmclinical@endeavorbiomedicines.com
  • Victoria
    • Melbourne, Victoria, Australia, 3004
      • Recruiting
      • Research Site
      • Contact: Endeavor Clinical Trials; Phone Number: 1-858-727-3199; Email: ebmclinical@endeavorbiomedicines.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Participants are reproductively sterile.
• Body Mass Index (BMI) ≥ 18.5 and ≤ 32 kg/m2 and body weight ≥ 50 kg at study start.
• Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, or electrocardiograms (ECGs) prior to dosing, as deemed by the Investigator.
• Able to swallow multiple capsules and tablets.
• Participants are willing to remain on study treatment for the duration of the study and comply with all study days and procedures.
• Participants willing to sign and have a full understanding of the informed consent.
• Participants must be willing to be sequestered for the time period indicated for their respective cohort.

Exclusion Criteria:

• Chronic or current use of any prescription or over the counter medications; or acute use of prescription medications within 14 days or 5 half-lives, whichever is longer, or over the counter medications within 7 days or 5 half-lives, whichever is longer, prior to study start, or planned use during all study periods.
• Participant is unwilling to refrain from fruits (including juices) that inhibit CYP3A4, including grapefruit, Seville orange, pomelo, or star fruit, beginning 7 days prior to study start through end of study.
• Active infection with hepatitis B or C, or human immunodeficiency virus (HIV) during screening.
• Current alcohol or drug abuse.
• Smoking or other nicotine use (including but not limited to vaping, nicotine patch, nicotine gum or nicotine lozenge) within 3 months prior to screening, current smoker, or unwillingness to refrain from smoking for the duration of the study.

• History or presence (per participant history) of:

  1. Autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus
  2. Thrombophlebitis or deep vein thrombosis
  3. Hematologic or coagulation disorders
  4. Liver disease or dysfunction; Gilbert's syndrome
  5. Renal dysfunction or glomerulonephritis
  6. Coronary artery disease
  7. Diverticular disease
  8. Congestive heart failure or ventricular dysfunction
  9. Clinically significant cardiovascular, gastrointestinal, pulmonary, endocrine, central nervous system disorders, or other major active and uncontrolled disease in the opinion of the Investigator.
• History of malignancy of any type, other than in situ cervical cancer or surgically excised non-melanomatous skin cancers, within 5 years before study start.
• Participation in a clinical research trial that included the receipt of an investigational agent or any experimental procedure within 30 days or 5 half-lives, whichever is longer, prior to screening, during screening, or planned participation in any such trial while participating in this study.
• Major surgery requiring hospitalization (according to the Investigator) performed within 3 months prior to screening, or planned during the course of the trial.
• Participants with clinically significant cardiac abnormalities including but not limited to: has pacemaker; or is not in sinus rhythm during screening; or has a left bundle branch block or bifascicular block during screening; or any prior history of ventricular arrhythmia or torsades de pointes.
• Participant is unwilling to adhere to the on-study diet provided by the clinical site during study participation.
• Females who are pregnant or nursing.
• Participants that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final dose of any study treatment.
• Males who are unwilling to refrain from sperm donation for the duration of the study and for 95 days after their final dose of any study treatment.
• Females who are unwilling to refrain from egg donation for the duration of the study and for 95 days after their final dose of any study treatment.
• Participants with a history of a severe allergic reaction or anaphylactic reaction or known hypersensitivity to any component of taladegib (all cohorts), nintedanib (Cohort 1), or pirfenidone (Cohorts 2 and 3).
• Participants who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study investigative site or the study Sponsor.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1 (effect of nintedanib on taladegib pharmacokinetics); This cohort will receive multiple days of nintedanib twice a day to see its effect on a single dose of taladegib.	Drug: taladegib; low, medium or high dose tablet administered once, or once a day; Other Names: ENV-101; Drug: nintedanib; 150 mg capsule administered twice a day
Experimental: Cohort 2 (effect of pirfenidone on taladegib pharmacokinetics); This cohort will receive multiple days of pirfenidone three times a day to see its effect on a single dose of taladegib.	Drug: taladegib; low, medium or high dose tablet administered once, or once a day; Other Names: ENV-101; Drug: pirfenidone; One, two or three 267 mg tablets administered three times a day; Drug: pirfenidone; Three 267 mg tablets administered once
Experimental: Cohort 3 (effect of taladegib on pirfenidone pharmacokinetics); This cohort will receive multiple days of taladegib once a day to see its effect on a single dose of pirfenidone.	Drug: taladegib; low, medium or high dose tablet administered once, or once a day; Other Names: ENV-101; Drug: pirfenidone; One, two or three 267 mg tablets administered three times a day; Drug: pirfenidone; Three 267 mg tablets administered once
Experimental: Cohort 4 (measure taladegib pharmacokinetics); This cohort will receive a single dose of taladegib to measure its pharmacokinetic profile.	Drug: taladegib; low, medium or high dose tablet administered once, or once a day; Other Names: ENV-101

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cohort 1: Taladegib (ENV-101) maximum blood concentration (Cmax) after administration alone and after coadministration with nintedanib		Day 1 and Day 13
Cohort 1: Time of taladegib maximum blood concentration (Tmax) after administration alone and after coadministration with nintedanib		Day 1 and Day 13
Cohort 1: Taladegib absorption to time t (AUC[0-t]) after administration alone and after coadministration with nintedanib	AUC[0-t] represents "area under the concentration-time curve" and measures the amount of drug that is present in the blood from the time of administration to a given time t	Day 1 and Day 13
Cohort 1: Taladegib total absorption (AUC[0-infinity]) after administration alone and after coadministration with nintedanib		Day 1 and Day 13
Cohort 1: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with nintedanib		Day 1 and Day 13
Cohort 1: Taladegib half-life in the blood (T1/2) after administration alone and after coadministration with nintedanib		Day 1 and Day 13
Cohort 1: Elimination rate constant (K[el]) for taladegib after administration alone and after coadministration with nintedanib	K[el] represents the fraction of a drug that is removed from the body per unit of time.	Day 1 and Day 13
Cohort 1: Apparent oral clearance (CL/F) of taladegib after administration alone and after coadministration with nintedanib	Apparent oral clearance represents the volume of plasma cleared of drug per unit time after oral administration.	Day 1 and Day 13
Cohort 1: Apparent volume of distribution (Vz/F) of taladegib after administration alone and after coadministration with nintedanib	Apparent volume of distribution signifies how extensively a drug distributes throughout the body, accounting for bioavailability.	Day 1 and Day 13
Cohort 2: Taladegib maximum blood concentration (Cmax) after administration alone and after coadministration with pirfenidone		Day 1 and Day 27
Cohort 2: Time of taladegib maximum blood concentration (Tmax) after administration alone and after coadministration with pirfenidone		Day 1 and Day 27
Cohort 2: Taladegib absorption to time t (AUC[0-t]) after administration alone and after coadministration with pirfenidone		Day 1 and Day 27
Cohort 2: Taladegib total absorption (AUC[0-infinity]) after administration alone and after coadministration with pirfenidone		Day 1 and Day 27
Cohort 2: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with pirfenidone		Day 1 and Day 27
Cohort 2: Taladegib half-life in the blood (T1/2) after administration alone and after coadministration with pirfenidone		Day 1 and Day 27
Cohort 2: Elimination rate constant (K[el]) for taladegib after administration alone and after coadministration with pirfenidone		Day 1 and Day 27
Cohort 2: Apparent oral clearance (CL/F) of taladegib after administration alone and after coadministration with pirfenidone		Day 1 and Day 27
Cohort 2: Apparent volume of distribution (Vz/F) of taladegib after administration alone and after coadministration with pirfenidone		Day 1 and Day 27
Cohort 3: Pirfenidone maximum blood concentration (Cmax) after administration alone and after coadministration with taladegib		Day 1 and Day 6
Cohort 3: Time of pirfenidone maximum blood concentration (Tmax) after administration alone and after coadministration with taladegib		Day 1 and Day 6
Cohort 3: Pirfenidone absorption to time t (AUC[0-t]) after administration alone and after coadministration with taladegib		Day 1 and Day 6
Cohort 3: Pirfenidone total absorption (AUC[0-infinity]) after administration alone and after coadministration with taladegib		Day 1 and Day 6
Cohort 3: Pirfenidone extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with taladegib		Day 1 and Day 6
Cohort 3: Pirfenidone half-life in the blood (T1/2) after administration alone and after coadministration with taladegib		Day 1 and Day 6
Cohort 3: Elimination rate constant (K[el]) for pirfenidone after administration alone and after coadministration with taladegib		Day 1 and Day 6
Cohort 3: Apparent oral clearance (CL/F) of pirfenidone after administration alone and after coadministration with taladegib		Day 1 and Day 6
Cohort 3: Apparent volume of distribution (Vz/F) of pirfenidone after administration alone and after coadministration with taladegib		Day 1 and Day 6
Cohort 4: Taladegib maximum blood concentration (Cmax) after administration alone		Day 1
Cohort 4: Time of taladegib maximum blood concentration (Tmax) after administration alone		Day 1
Cohort 4: Taladegib absorption to time t (AUC[0-t]) after administration alone		Day 1
Cohort 4: Taladegib total absorption (AUC[0-infinity]) after administration alone		Day 1
Cohort 4: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration alone		Day 1
Cohort 4: Taladegib half-life in the blood (T1/2) after administration alone		Day 1
Cohort 4: Elimination rate constant (K[el]) for taladegib after administration alone		Day 1
Cohort 4: Apparent oral clearance (CL/F) of taladegib after administration alone		Day 1
Cohort 4: Apparent volume of distribution (Vz/F) of taladegib after administration alone		Day 1

Collaborators and Investigators

• Sponsor: Endeavor Biomedicines, Inc.
• Investigators: Study Director: Lisa Lancaster, M.D., Endeavor Biomedicines

Study record dates

Study Major Dates

• Study Start (Actual): April 28, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026

Study Registration Dates

• First Submitted: March 2, 2026
• First Submitted That Met QC Criteria: March 2, 2026
• First Posted (Actual): March 6, 2026

Study Record Updates

• Last Update Posted (Actual): May 15, 2026
• Last Update Submitted That Met QC Criteria: May 13, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: pharmacokinetics; drug-drug interaction; taladegib; ENV-101
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Interstitial; Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis; pirfenidone; LY2940680; nintedanib
• Other Study ID Numbers: ENV-IPF-104

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes